4 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $559000 | -$89M | 61.5% | -16292.8% | -$62M | — | $11M |
| 2024 | $43M | -$45M | 72.7% | -146.4% | -$68M | — | $121M |
| 2023 | $32M | -$54M | 59.3% | -203.5% | -$50M | — | $69M |
| 2022 | $22M | -$50M | 37.8% | -281.9% | -$57M | — | — |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $422000 | -$15M | 97.4% | -3729.1% | -$16M | — | $6M |
| Dec '25 | $34000 | -$12M | 64.7% | -36650.0% | -$17M | — | $11M |
| Sep '25 | $159000 | -$21M | 59.7% | -16505.7% | -$11M | — | $82M |
| Jun '25 | $224000 | -$27M | 62.1% | -10697.8% | -$22M | — | $42M |
| Mar '25 | $142000 | -$29M | 62.0% | -20006.3% | -$12M | — | $65M |
| Dec '24 | $25M | $12M | 91.9% | -17.2% | -$28M | — | $121M |
| Sep '24 | $1M | -$36M | -142.9% | -2002.5% | -$26M | — | — |
| Jun '24 | $756000 | -$20M | -340.9% | -3093.7% | -$5M | — | — |
| Mar '24 | $16M | -$2M | 82.2% | -35.6% | -$9M | — | — |
How the market has priced SLN against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 3 years, Silence Therapeutics Plc's revenue has declined 70.4% per year. These are computed facts, not advice.
As of FY2025, Silence Therapeutics Plc reported — of total debt against $11M of cash.
In FY2025, gross margin was 61.5%, operating margin -16292.8%, and net margin -15851.5%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.